Allogene Therapeutics, Inc.
- Apr 19, 2018 · D · $411,770,409 sold of $411,770,409 · 23 investors · min. No minimum reported · role: Director EDGAR ↗
Raised $411.8M from 23 investors (100% of the $411.8M target) as of the latest filing. Owen is listed as director.
Sources
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.